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There is increasing evidence that tea and its non-caﬀeine components (primarily ﬂavonoids) contribute to
cardiovascular health. Randomized controlled trials have shown that tea can improve cardiovascular
disease risk factors. We have previously reported a non-caﬀeine associated beneﬁcial eﬀect of regular
black tea consumption on blood pressure and its variation. Objective: To explore the non-caﬀeine
associated eﬀects of black tea on body weight and body fat distribution, and cardiovascular disease related
metabolic outcomes. Design: regular tea-drinking men and women (n ¼ 111; BMI 20–35 kg m2) were
recruited to a randomized controlled double-blind 6 month parallel-designed trial. Participants consumed
3 cups per day of either powdered black tea solids (tea) or a ﬂavonoid-free ﬂavour- and caﬀeine-matched
placebo (control). Body weight, waist- and hip-circumference, endothelial function and plasma biomarkers
were assessed at baseline, 3 months and 6 months. Results: Compared to control, regular ingestion of
black tea over 3 months inhibited weight gain (0.64 kg, p ¼ 0.047) and reduced waist circumference
(1.88 cm, P ¼ 0.035) and waist-to-hip ratio (0.03, P ¼ 0.005). These eﬀects were no longer signiﬁcant
at 6 months. There were no signiﬁcant eﬀects observed on fasting glucose, insulin, plasma lipids or
endothelial function. Conclusion: Our study suggests that short-term regular ingestion of black tea over 3
months can improve body weight and body fat distribution, compared to a caﬀeine-matched control
beverage. However, there was no evidence that these eﬀects were sustained beyond 3 months.1. Introduction
Besides water, tea is the most popular beverage in the world. In
relation to cardiovascular disease (CVD) tea is generally
described according to two types: green tea and black tea. Both
green and black tea are brewed by infusion of leaves from the
tea plant, Camellia sinensis, with boiled water. The brewed
beverage contains a wide range of phytochemicals, particularly
polyphenols, with potential benecial bioactivities following
consumption. Tea also contains caﬀeine, about 25 to 50 mg per
cup.1 Originating from the same plant, green and black tea have
overlapping phytochemical proles. However, diﬀerences in
product processing of the teas give some distinct diﬀerencesc Medical Sciences, Faculty of Medicine,
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hemistry 2014that may aﬀect outcomes diﬀerently, such as those associated
with CVD risk.2
Epidemiological data suggest that black and green tea may
reduce the risk of both coronary heart disease and stroke by
between 10 and 20%.2 Experimental and clinical trial data
generally indicate either neutral or benecial eﬀects on risk
factors and pathways linked to the development of CVD.2 While
there is growing evidence that regular ingestion of green tea
catechins with caﬀeine can reduce body weight and visceral
fatness3–9 there is only one study linking black tea with body
weight and body fat distribution.10
In this trial we have previously demonstrated that regular
ingestion of black tea can result in lower blood pressure11 and
lower blood pressure variation.12 The objective of the current
analysis was to assess the eﬀects of longer-term regular
consumption of black tea, over 6 months, on body weight and
body fat distribution. We also assessed eﬀects of tea on several
other cardiovascular disease-related metabolic outcomes.2. Methods
2.1 Subjects and study design
A randomized placebo-controlled double-blind 6month parallel
designed trial was performed (Fig. 1). Men and women aged 35Food Funct., 2014, 5, 1613–1620 | 1613
Fig. 1 Participants included at each stage of the trial.
Table 1 Contents, tea and placebo (per cup)
Ingredient (mg) Control Tea
Polyphenols 0 143
Total caﬀeine 33 32
Tea solids — 498
Caﬀeine added 37 —
Caramel colour 90 —
Tea avour 10 —
Sugar [sucrose] 1363 1403
Total weight of sachet 1500 1900
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View Article Onlineto 75 years, who were regular tea drinkers, with a body mass
index of 19 to 35 (calculated as weight in kilograms divided by
height in meters squared) and a daytime ambulatory systolic
blood pressure between 115 and 150 mm Hg at screening were
recruited from the general population.
Participants were enrolled in the study by a clinical trials
coordinator. Prior to the 4 week run-in period volunteers were
randomized (1 : 1) using computer generated random numbers.
Randomization codes were generated by a statistician working
with Unilever Research and Development, Vlaardingen inde-
pendent of study investigators. Randomization codes consisted
of a four-digit number linked to the study products: either
control or active tea. Study products were sachets labeled with
10 diﬀerent randomly generated numbers of four digits: ve
linked to control and ve linked to active tea. This prevented
volunteers from nding out what product they were consuming
by talking to each other. This also maintained blinding of
researchers performing measurements during the study. A total
of 120 envelopes, numbered 1 to 120, each containing one of
those 4 digit numbers, 60 linked to control and 60 linked to
active tea, were produced independent of study researchers.
These envelopes were then provided to the lead investigator
(JMH) who was not involved directly in performing any outcome
measurements. Envelopes were opened in consecutive order by
the lead investigator as each participant entered into the study.
Of the 111 recruited participants 56 were randomly chosen to
consume 3 cups per day of black tea. The tea was prepared from
a single batch of powdered black tea provided to participants as
single serve sachets. Each sachet contained black tea solids
containing 429 mg of polyphenols assessed as gallic acid
equivalents measured using the folin–ciocalteu reagent with
gallic acid as a standard13 and 96 mg of caﬀeine (measured by
HPLC).14 The contents of each sachet were dissolved in hot
water prior to ingestion. 55 participants were randomly chosen
to consume the placebo beverage, which wasmatched in avour
and caﬀeine content, containing no tea solids (Table 1).1614 | Food Funct., 2014, 5, 1613–1620Following randomization, participants followed a low-avo-
noid diet during a 4 week run-in period and throughout the 6
month intervention. During run-in, the participants consumed
3 cups per day of regular leaf tea.
A total of 77 participants completed the trial (Fig. 1). The
reasons for withdrawal in the control group were medical issues
unrelated to the trial (n¼ 5), moving interstate (n¼ 1), unable to
drink the beverage (n ¼ 2) and personal issues (n ¼ 8). The
reasons for withdrawal in the tea group were incomplete base-
line data (n ¼ 1), medical issues unrelated to the trial (n ¼ 6),
moving interstate (n ¼ 1), unable to drink the beverage (n ¼ 2)
and personal issues (n ¼ 8).2.2 Dietary restrictions
In order to ensure that the background avonoid intake in
both groups was less than 800–1000 mg per day (estimated
to average 500 mg per d), the intake of a limited number of
high avonoid foods and beverages (tea, coﬀee, red wine,
chocolate, fruit juices) were restricted during a 4 week
baseline period and throughout the study. Participants
did not consume any additional tea during the study, they
did not consume dark chocolate and were limited to less than
25 g per day of milk chocolate (including chocolate bever-
ages), the wine consumed was white rather than red, the
intake of fruit juices was limited to less than 4 glasses
per week, and coﬀee intake was limited to less than 1 cup
per day on average (<7 cups per week). A dietitian monitored
each participant's progress every 4 weeks to ensure
compliance.
All procedures followed were in accordance with the ethical
standards of the University of Western Australia Ethics
Committee and the trial was registered at the Australian New
Zealand Clinical trials Registry ACTRN12607000543482.2.3 Body weight and food intake
Body weight was monitored throughout the intervention.
Height was measured using a wall-mounted stadiometer. All
waist and hip measurements were measured by a trained
technician. A 3 day weighed food record was completed by all
participants at baseline and at the end of 3 months and 6
months.This journal is © The Royal Society of Chemistry 2014
Table 2 Participant characteristicsa
Control (n¼39) Tea (n ¼ 38)
Mean SD Mean SD
Age 55.4 9.8 55.9 10.9
Gender
Males (n) 14 13
Females (n) 25 25
Tea biomarker
4OMGA (mg mmol1
creatinine)
43 25 51 33
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View Article Online2.4 Plasma and urinary biomarkers
Single biochemical measurements were performed at baseline,
3 months and 6 months. Venous blood samples were collected
following a 12 hour fast from the antecubital vein of the fore-
arm. A 24 hour urine collection was also performed. All
biochemical and haematology analyses were performed in the
PathWest Laboratory at Royal Perth Hospital, Western Aus-
tralia. Analyses of lipids, glucose, insulin and creatinine were
performed on samples stored at 80 C, in a single batch to
reduce variability using routine laboratory methods. Serum
total cholesterol, HDL cholesterol and triglycerides were
measured using a routine enzymatic colorimetric test with a
fully automated analyser (Roche Hitachi 917; Roche Diagnostics
Australia Pty Ltd., Castle Hill, NSW, Australia). Serum LDL
cholesterol was calculated using the Friedewald equation.15
Serum glucose was measured using a hexokinase/G-6-PDH
method (Abbott Laboratories) using a fully automated analyser
(Architect c16000). The assay coeﬃcient of variation was 2.7%.
Serum insulin was analysed by immunoassay (Abbott Labora-
tories) using a fully automated analyser (Architect c16000), with
an assay coeﬃcient of variation of 1.5%. The homeostasis
model assessment (HOMA) insulin sensitivity score was calcu-
lated with the following formula: [serum glucose (mmol L1) 
serum insulin (mU mL1)/22.5].16 Serum and urinary creatinine
were analysed using kinetic colorimetric tests (Roche, Indian-
apolis) with an automated analyser (Roche Hitachi 917). Esti-
mated glomerular ltration rate was used as an indicator of
renal function. Glomerular ltration rate was estimated using
creatinine clearance, which was calculated in mL min1 as
urinary creatinine concentration multiplied by 24 h urine
volume, divided by plasma creatinine concentration multiplied
by 24 h multiplied by 60 min. Urinary 4-O-methylgallic acid
(4OMGA) concentrations were measured by gas chromatog-
raphy mass spectrometry according to a previously described
method17 and the values were then divided by urinary creatinine
concentration. The 24 h 4OMGA excretion is a biomarker of
black tea intake and was used to assess compliance.Body weight and anthropometry
Waist-to-hip ratio 0.8 0.1 0.8 0.1
Waist-circumference (cm) 80.9 10.2 81.5 10.6
Hip-circumference (cm) 100.4 5.9 98.4 7.9
BMI (kg m2) 25.0 3.1 24.8 3.5
Weight (kg) 72.4 11.0 71.2 11.6
Glucose metabolism
Glucose (mmol L1) 5.1 0.5 5.3 0.9
Insulin (mU L1) 6.5 3.6 8.1 9.2
HOMA 1.5 1.0 2.2 3.4
Blood lipids/lipoproteins
Triglycerids (mmol L1) 1.1 0.6 1.2 0.5
Cholesterol (mmol L1) 5.2 0.8 5.1 0.8
HDL (mmol L1) 1.4 0.1 1.4 0.1
LDL (mmol L1) 3.3 0.1 3.1 0.1
Endothelial function
Peak FMD (%) 7.8 2.9 8.2 3.8
Max FMD diameter (mm) 3.6 0.5 3.5 0.5
a 4OMGA; urinary 4-O-methylgallic acid, HDL; high density lipoprotein,
LDL; high density lipoprotein; FMD; ow-mediated dilatation. p < 0.005.2.5 Blood pressure and endothelial function
Blood pressure measures included mean 24 hour ambulatory
systolic and diastolic blood pressure and heart rate. Day time
(awake), night time (asleep) and early morning blood pressure
and heart rate was measured as previously described.11
Results of eﬀects on blood pressure have previously been
reported.11,12
Endothelial function measurement and analysis was per-
formed by a trained technician, who was blinded to the treat-
ment allocation according to a previously published
method.18,19 Endothelium-dependent ow-mediated dilatation
of the brachial artery (FMD) was measured following an
ischemic stimulus. Analysis was carried out using a semi-
automated edge detection soware system. Measurements of
endothelium-dependent ow-mediated dilatation of the
brachial artery were performed at 30 second intervals for 4
minutes. Peak response was also assessed and was used for
analysis of diﬀerences.This journal is © The Royal Society of Chemistry 20142.6 Statistical analysis
The sample size for this study was based on the primary
outcome of 24 hour ambulatory systolic blood pressure. We
estimated 100 participants (50 participants per group) would
provide greater than 90% power at alpha 0.05 to detect a 3 mm
Hg diﬀerence in 24 hour systolic blood pressure. The primary
outcome from this study, blood pressure, has already been
published.12 The current analysis represents an analysis of pre-
specied secondary outcomes for this study. The population
was limited to the per protocol population which was dened as
all participants who completed the 6 month study, had
measurements performed for the relevant outcome and
consumed at least 70% of the study product.
The eﬀect of black tea on BMI, waist to hip circumference
ratio, waist circumference, hip circumference, glucose, insulin,
HOMA, triglycerides, cholesterol, HDL and LDL were analysed
using mixed model analysis for longitudinal data sets i.e. each
subject was measured repeatedly on the same outcome
(at baseline, 3 and 6 months). The “mixed” command for
linear mixed models in STATA 12 (StataCorp) with a random
intercept was used treating time as a categorical parameter,
with the following parameterization: b0month+ b1treatment+Food Funct., 2014, 5, 1613–1620 | 1615
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View Article Onlineb2(month*treatment). Where the month*treatment was signif-
icant the diﬀerence between the treatment groups with regards
to changes in the tted mean over time are given in the text. The
diﬀerence between each group at each time point was tested
using model-based contrasts. All models were applied on per
protocol samples. Fitted means and SE for each time and group
generated by the mixed model analysis are reported. Signi-
cance was determined by P < 0.05.
3. Results
3.1 Baseline characteristics and compliance
Patient's characteristics and baseline levels of plasma/urine
variables and endothelial function are presented in Table 2. In
the tea group 35 out of 38 were Caucasian and 3 of unknown
ethnicity. In the control group 38 out of 39 were Caucasian and
1 was of Asian ethnicity. Compliance was conrmed by the
substantially higher increase in the levels of urinary 4OMGA
(P < 0.001) in the tea group compared to caﬀeine matched
controls (Table 3).
3.2 Tests for diﬀerential change over time between the
intervention groups
3.2.1 Body composition and anthropometry. Compared to
controls, regular ingestion of black tea over the rst 3 months
inhibited gain of weight (0.64 kg, p ¼ 0.047) and BMI (0.22
kg m2, P¼ 0.042) and reduced waist circumference (1.88 cm,
P ¼ 0.035) and waist-to-hip ratio (0.03, P ¼ 0.005) (Table 3).
There was no signicant diﬀerence between groups in the
change between baseline and 6 months (Table 3). ESI Table 1†Table 3 Tea biomarker and anthropometry measures – mixed model a
t
Control
n Fitted mean SE
Tea biomarker
4OMGA mg mmol1 creatinine 0 39 43 4
3 39 7 4
6 39 7 4
Anthropometry
Waist-to-hip ratio 0 39 0.81 0.0
3 38 0.82 0.0
6 39 0.80 0.0
Waist (cm) 0 39 80.91 1.6
3 38 81.72 1.6
6 39 79.78 1.6
Hip (cm) 0 39 100.41 1.0
3 38 99.46 1.0
6 39 99.12 1.0
BMI (kg m2) 0 39 24.97 0.5
3 39 25.19 0.5
6 39 25.02 0.5
Weight (kg) 0 39 72.44 1.8
3 39 73.08 1.8
6 39 72.56 1.8
a Fitted means from the mixed models with SE. The p values are obtained
Time*group corresponds to the diﬀerence in slopes (eﬀects of time) betw
1616 | Food Funct., 2014, 5, 1613–1620shows the total output from the mixed model analysis. There
were no signicant diﬀerences between groups with regard to
changes in energy intakes throughout the study (P ¼ 0.42 at 3
months, P ¼ 0.40 at 6 months, data not shown). In addition
macro-nutrient intakes were not signicantly altered during the
intervention.
3.2.2 Glucose metabolism and plasma lipids. There was a
non-signicant trend for the intake of black tea, relative to
control, to result in a decrease in fasting blood glucose (0.2
mM mL1, P ¼ 0.089) at 3 months (Table 4). The magnitude of
diﬀerences between the groups was smaller at 6 months. In
addition, no signicant diﬀerences were found over the inter-
vention period between the tea group and control for triglycer-
ides, cholesterol, HDL cholesterol or LDL cholesterol (Table 4).
ESI Table 1† shows the total output from the mixed model
analysis.
3.2.3 Endothelial function. Endothelial function was
assessed as maximum diameter (max FMD diameter) and
maximum dilation relative to vessel size (Peak FMD). No
signicant diﬀerences were found between the groups over time
(Table 5). ESI Table 1† shows the total output from the mixed
model analysis. In addition there were no diﬀerences between
the treatment groups at 3 months or at 6 months.4. Discussion
Epidemiological and intervention studies provide evidence
that consumption of tea can reduce blood pressure.20 We
have previously reported from this study that regular black
tea consumption (3 cups per day) for 6 months resulted innalysisa
Tea Mixed model
n Fitted mean SE Time*group p
38 51 4
36 61 4 45 <0.001*
37 70 4 55 <0.001*
2 38 0.83 0.02
2 38 0.82 0.02 0.03 0.005*
2 36 0.81 0.02 0.02 0.129
9 38 81.50 1.71
9 38 80.43 1.71 1.88 0.035*
9 36 80.30 1.71 0.07 0.937
8 38 98.38 1.10
9 38 98.45 1.10 1.01 0.272
8 36 98.89 1.10 1.80 0.051
2 38 24.76 0.53
2 38 24.76 0.53 0.22 0.042*
2 37 24.94 0.53 0.13 0.225
0 38 71.17 1.83
0 38 71.17 1.83 0.64 0.047*
0 37 71.70 1.83 0.41 0.207
from the month*treatment interaction for 3 and 6 months respectively.
een tea and controls. t ¼ Time (months). *p-value < 0.05.
This journal is © The Royal Society of Chemistry 2014
Table 4 Glucose metabolism and blood lipids – mixed model analysisa
t
Control
n
Tea
SE
Mixed model
n Fitted mean SE Fitted mean Time* group p
Glucose metabolism
Glucose (mmol L1) 0 39 5.09 0.09 38 5.31 0.09
3 39 5.10 0.09 38 5.12 0.09 0.20 0.089
6 39 5.09 0.09 37 5.24 0.09 0.07 0.572
Insulin (mU L1) 0 39 6.53 0.82 38 8.11 0.83
3 39 6.53 0.82 38 6.89 0.83 1.22 0.238
6 39 6.15 0.82 37 6.80 0.83 0.94 0.367
HOMA 0 39 1.52 0.26 38 2.16 0.27
3 39 1.52 0.26 38 1.60 0.27 0.55 0.177
6 39 1.42 0.26 37 1.62 0.27 0.43 0.294
Blood lipids/lipoproteins
Trig (mmol L1) 0 39 1.12 0.09 38 1.15 0.09
3 39 1.03 0.09 38 1.08 0.09 0.02 0.819
6 39 1.12 0.09 37 1.11 0.09 0.05 0.566
Total Chol (mmol L1) 0 39 5.24 0.13 38 5.08 0.13
3 39 5.30 0.13 38 5.27 0.13 0.13 0.263
6 39 5.28 0.13 37 5.15 0.13 0.03 0.764
HDL-Chol (mmol L1) 0 39 1.42 0.05 38 1.40 0.05
3 39 1.49 0.05 38 1.48 0.05 0.01 0.760
6 39 1.47 0.05 37 1.46 0.05 0.01 0.850
LDL-Chol (mmol L1) 0 39 3.30 0.12 38 3.14 0.12
3 39 3.34 0.12 38 3.29 0.12 0.11 0.246
6 39 3.29 0.12 37 3.18 0.12 0.05 0.609
a Fitted means from the mixed models with SE. The p values are obtained from the month*treatment interaction for 3 and 6 months respectively.
Time*group shows the diﬀerence in eﬀects of time between tea and controls. Tests for absolute diﬀerence between treatment groups at 3 and 6
months. Trig ¼ triglycerides; Chol ¼ cholesterol.
Table 5 Endothelial function – mixed model analysisa
t
Control
n
Tea
SE
Mixed model
n Fitted mean SE Fitted mean Time* group p
Endothelial function
Peak FMD (%) 0 39 3.57 0.08 38 3.50 0.08
3 39 3.58 0.08 38 3.53 0.08 0.02 0.244
6 39 3.62 0.08 37 3.53 0.08 0.02 0.294
Max FMD diam.
(mm)
0 39 7.82 0.53 38 8.21 0.54
3 39 8.14 0.53 38 7.94 0.54 0.6 0.710
6 39 8.23 0.53 37 8.08 0.54 0.5 0.573
a Fitted means from the mixed models with SE. The p values are obtained from the month*treatment interaction for 3 and 6 months respectively.
Time*group corresponds to the diﬀerence in slopes (eﬀects of time) between tea and controls.
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View Article Onlinesignicantly lower systolic blood pressure, diastolic blood
pressure and rate of blood pressure variation11,12 compared
to control (equal amounts of caﬀeine but without other
black tea constituents). In this analysis we demonstrate that
intake of black tea, compared to control, altered the
change in body weight and body fat distribution over 3
months. There was also weak evidence for improvement
in glucose metabolism during this time. However, the
eﬀects on anthropometric measures during the rst 3
months were not maintained over the full 6 months of
the trial.This journal is © The Royal Society of Chemistry 2014Adverse CVD risk is associated with obesity and particularly
with abdominal obesity.21 In addition, waist circumference and
waist to hip circumference ratio have been suggested to reect
the amount of visceral fatness.22 Compared to the control group
the tea group had a small reduction in body weight, waist
circumference and waist-to-hip ratio over time, up to 3 months,
suggesting that tea intake may potentially benet visceral fat
deposits. There are several reports on the eﬀects of green tea
intake on body weight and body composition.3–9,23,24 Several of
these studies were up to 12 weeks in duration. However, the only
controlled clinical study on black tea and eﬀects onFood Funct., 2014, 5, 1613–1620 | 1617
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View Article Onlineanthropometry published so far is a 12 week double blind
randomized controlled trial of 36 pre-obese Japanese adults
intervened with black tea extract (BTE).10 In line with our nd-
ings, they found a signicant decrease in visceral fatness as
measured by computed tomography scanning. In addition they
found that BMI decreased signicantly in the BTE group
compared to controls.10 Our results were not able to provide
evidence that these potential benets were maintained beyond
3 months, out to 6 months. The reason for this is not clear.
There are limited studies on the eﬀect of tea on blood
glucose. Intake of black tea has been reported to lower blood
glucose in healthy subjects and improve scores of insulin
sensitivity.25 A short-term clinical trial of healthy volunteers
showed that intake of instant black tea decreased fasting blood
glucose and increased fasting insulin in response to an oral
glucose load.25 A clinical intervention study with oolong tea
demonstrated a lowering of blood glucose in type 2 diabetic
subjects.26 In vitro studies suggest a mechanism for how tea
catechins can promote blood glucose regulation through
induction of glucose transporter (GLUT)4 translocation in
skeletal muscle.27 Our results provide only weak evidence for a
benet of black tea on glucose concentrations. We did not nd
any diﬀerential eﬀects on serum cholesterol levels between the
tea group and the caﬀeine controlled placebo. Most human
intervention studies with black tea or tea extracts have found
little or no change in total serum cholesterol levels. Out of the
seven randomised controlled trials on black tea only one
showed cholesterol lowering eﬀects.28
Interestingly, in the present study, the control group and the
tea group had a similar pattern of increased HDL level over
time. Conicting results have been reported on the eﬀect of
black tea on HDL. Some studies nd no eﬀect of black tea intake
on HDL29,30 while others have reported moderate increase in
HDL when comparing a group consuming black tea to controls
consuming hot water (without caﬀeine)31.
FMD is used to directly assess the function of the arterial
wall. In the present study we did not nd any eﬀects on FMD. In
the tea group, compared to control, neither Max FMD diameter
nor Peak FMD was altered. This nding contradicts most other
studies on black tea and FMD.32 A meta-analysis from 2011 of 9
human intervention studies where the eﬀect of green and black
tea on endothelial function had been measured by FMD
concluded that moderate consumption of tea substantially and
signicantly enhances FMD.33 The reason for the lack of benet
in the current study may relate to the level of FMD at baseline,
which was close to 8%. In our hands, a healthy normolipidae-
mic, normotensive population has an FMD of approximately 8%
(unpublished data). Thus, the FMD in the current population
was essentially normal. There is evidence that it is diﬃcult to
chronically improve already normal endothelial function.34 In
addition, the majority of studies reported in the literature
measured the acute eﬀect of tea on FMD, which has not been
determined in the current study. Therefore, an acute-on-chronic
eﬀect of tea on FMD in the current study cannot be excluded. An
improved FMD aer chronic tea consumption (i.e. 4 weeks) has
been demonstrated in subjects with impaired endothelial
function (baseline FMD 6.0%).35,361618 | Food Funct., 2014, 5, 1613–16205. Limitations
Although we found no signicant diﬀerences between the
groups at baseline we cannot exclude a possible regression to
the mean situation for waist to hip ratio and waist circumfer-
ence. However the mixed model analyses were performed
including a random intercept in the model. Although decreased
waist to hip ratio and waist circumference indicate decreased
visceral fatness, future studies should potentially include
computed tomography or magnetic resonance imaging to
evaluate the eﬀects on the diﬀerent fat deposits. The risk of
developing CVD in response to diet may be highly dependent on
the particular genetic characteristics of an individual.37 Like-
wise, diﬀerences in the genetic background may dictate
diﬀerent response to tea intake. Variations in the genes (poly-
morphisms) involved in uptake, metabolism or excretion of
compounds from tea are likely to be associated to diﬀerential
eﬀects of tea intake. Information on such genotypes could add
another level to data interpretation.
Due to the long period of the intervention regular tea
drinkers were recruited for this study. However, the amount of
tea consumed daily varied between the volunteers. This made it
necessary to standardise the tea intake to 3 cups of regular tea
daily during the 4 week run-in period. Subsequently, subjects
were randomised to the placebo or tea group. As a consequence
the current study design combines the overall eﬀect of stand-
ardised ingestion of tea in the tea group and tea withdrawal in
the placebo group. It is not clear whether similar eﬀects might
be seen in a non-tea-drinking group.
6. Conclusion
This study demonstrates that intake of black tea may slightly
aﬀect body weight and body fat distribution as compared to
caﬀeine-matched control beverage. The results must be inter-
preted cautiously since the changes in anthropometry measures
were only small and the tea group did not end up having
signicantly lower levels of any of these parameters compared
to controls at 6 months. Because tea consists of hundreds of
diﬀerent compounds with potential bioactivity, many yet
unidentied, more work is needed to elucidate the biological
activity of black tea and also to identify the bioactive
compounds and their corresponding metabolites. Thus, the
potential long-term consequences of regular ingestion of black
tea on body weight and composition remain uncertain.
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